Germany: These 28 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024

Generic name: capsaicin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 14, 2023
Generic Entry Controlled by: Germany Patent 60,314,298

QUTENZA is a drug marketed by Averitas. There are seven patents protecting this drug.

This drug has eighty-five patent family members in twenty-nine countries. There has been litigation on patents covering QUTENZA

See drug price trends for QUTENZA.

The generic ingredient in QUTENZA is capsaicin. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the capsaicin profile page.

Generic name: bupropion hydrochloride; naltrexone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 29, 2023
Generic Entry Controlled by: Germany Patent 602,004,012,403

CONTRAVE is a drug marketed by Nalpropion. There are twenty patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and fifty-seven patent family members in forty-three countries. There has been litigation on patents covering CONTRAVE

See drug price trends for CONTRAVE.

The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.

Generic name: letermovir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 02, 2023
Generic Entry Controlled by: Germany Patent 10,319,612
Patent Title: Substituierte Dihydrochinazoline

PREVYMIS is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.

This drug has eighty-five patent family members in forty-five countries.

See drug price trends for PREVYMIS.

The generic ingredient in PREVYMIS is letermovir. One supplier is listed for this generic product. Additional details are available on the letermovir profile page.

Generic name: letermovir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 02, 2023
Generic Entry Controlled by: Germany Patent 502,004,003,052

PREVYMIS is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.

This drug has eighty-five patent family members in forty-five countries.

See drug price trends for PREVYMIS.

The generic ingredient in PREVYMIS is letermovir. One supplier is listed for this generic product. Additional details are available on the letermovir profile page.

Generic name: peginesatide acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 12, 2023
Generic Entry Controlled by: Germany Patent 602,004,020,610

OMONTYS is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug.

This drug has one hundred and fourteen patent family members in thirty-four countries.

The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Germany Patent 602,004,008,938

JANUMET is a drug marketed by Merck Sharp Dohme. There are four patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JANUMET

See drug price trends for JANUMET.

The generic ingredient in JANUMET is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.

Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Germany Patent 602,004,008,938

JANUMET XR is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUMET XR

See drug price trends for JANUMET XR.

The generic ingredient in JANUMET XR is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.

Generic name: sitagliptin phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Germany Patent 602,004,008,938

JANUVIA is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug and one Paragraph IV challenge. Twelve tentatively approved generics are ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUVIA

See drug price trends for JANUVIA.

The generic ingredient in JANUVIA is sitagliptin phosphate. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the sitagliptin phosphate profile page.

Generic name: simvastatin; sitagliptin phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Germany Patent 602,004,008,938

JUVISYNC is a drug marketed by Merck Sharp Dohme. There are four patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JUVISYNC

The generic ingredient in JUVISYNC is simvastatin; sitagliptin phosphate. There are forty drug master file entries for this API. Additional details are available on the simvastatin; sitagliptin phosphate profile page.

Generic name: elagolix sodium,estradiol,norethindrone acetate; elagolix sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2023
Generic Entry Controlled by: Germany Patent 602,004,016,516

ORIAHNN (COPACKAGED) is a drug marketed by Abbvie Inc. There are five patents protecting this drug.

This drug has thirty-eight patent family members in twenty-three countries. There has been litigation on patents covering ORIAHNN (COPACKAGED)

The generic ingredient in ORIAHNN (COPACKAGED) is elagolix sodium,estradiol,norethindrone acetate; elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium,estradiol,norethindrone acetate; elagolix sodium profile page.

Generic name: elagolix sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2023
Generic Entry Controlled by: Germany Patent 602,004,016,516

ORILISSA is a drug marketed by Abbvie Inc. There are six patents protecting this drug.

This drug has forty-three patent family members in twenty-four countries. There has been litigation on patents covering ORILISSA

See drug price trends for ORILISSA.

The generic ingredient in ORILISSA is elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium profile page.

Generic name: dabigatran etexilate mesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2023
Generic Entry Controlled by: Germany Patent 10,339,862
Patent Title: 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel (New crystalline forms of ethyl 3-(N-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-N-(2-pyridyl)amino)propionate methanesulfonate used for post-operative prophylaxis of deep vein thrombosis)

PRADAXA is a drug marketed by Boehringer Ingelheim. There are five patents protecting this drug and two Paragraph IV challenges. Ten tentatively approved generics are ready to enter the market.

This drug has two hundred and sixty-eight patent family members in fifty-two countries. There has been litigation on patents covering PRADAXA

See drug price trends for PRADAXA.

The generic ingredient in PRADAXA is dabigatran etexilate mesylate. There are twenty-six drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the dabigatran etexilate mesylate profile page.

Generic name: dabigatran etexilate mesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2023
Generic Entry Controlled by: Germany Patent 502,004,009,431

PRADAXA is a drug marketed by Boehringer Ingelheim. There are five patents protecting this drug and two Paragraph IV challenges. Ten tentatively approved generics are ready to enter the market.

This drug has two hundred and sixty-eight patent family members in fifty-two countries. There has been litigation on patents covering PRADAXA

See drug price trends for PRADAXA.

The generic ingredient in PRADAXA is dabigatran etexilate mesylate. There are twenty-six drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the dabigatran etexilate mesylate profile page.

Generic name: fluticasone propionate; salmeterol xinafoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2023
Generic Entry Controlled by: Germany Patent 602,004,031,459

AIRDUO RESPICLICK is a drug marketed by Teva Pharm. There are sixteen patents protecting this drug.

This drug has four hundred and nineteen patent family members in thirty-seven countries. There has been litigation on patents covering AIRDUO RESPICLICK

The generic ingredient in AIRDUO RESPICLICK is fluticasone propionate; salmeterol xinafoate. There are twenty-nine drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the fluticasone propionate; salmeterol xinafoate profile page.

Generic name: retapamulin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 03, 2023
Generic Entry Controlled by: Germany Patent 602,004,024,417

ALTABAX is a drug marketed by Almirall. There are two patents protecting this drug.

This drug has thirteen patent family members in six countries.

See drug price trends for ALTABAX.

The generic ingredient in ALTABAX is retapamulin. One supplier is listed for this generic product. Additional details are available on the retapamulin profile page.

Generic name: rivaroxaban
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2023
Generic Entry Controlled by: Germany Patent 10,355,461
Patent Title: Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung (Solid, high bioavailabilty oral formulations of N-substituted 5-chloro-2-thiophene-carboxamide derivative in hydrophilized form, useful for combating thrombo-embolic diseases)

XARELTO is a drug marketed by Janssen Pharms. There are five patents protecting this drug and two Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has one hundred and fifty-six patent family members in forty-seven countries. There has been litigation on patents covering XARELTO

See drug price trends for XARELTO.

The generic ingredient in XARELTO is rivaroxaban. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rivaroxaban profile page.

Generic name: rivaroxaban
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2023
Generic Entry Controlled by: Germany Patent 502,004,006,218

XARELTO is a drug marketed by Janssen Pharms. There are five patents protecting this drug and two Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has one hundred and fifty-six patent family members in forty-seven countries. There has been litigation on patents covering XARELTO

See drug price trends for XARELTO.

The generic ingredient in XARELTO is rivaroxaban. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rivaroxaban profile page.

Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: Germany Patent 5,852,057

NAMZARIC is a drug marketed by Allergan. There are twelve patents protecting this drug and three Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC

See drug price trends for NAMZARIC.

The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.

Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: Germany Patent 602,006,016,934

NAMZARIC is a drug marketed by Allergan. There are twelve patents protecting this drug and three Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC

See drug price trends for NAMZARIC.

The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.

Generic name: fosdenopterin hydrobromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: Germany Patent 102,004,004,642
Patent Title: Produktion, Gewinnung und therapeutischer Einsatz des Molybdopterin-Derivats Precursor Z zur Therapie der Stoffwechselerkrankung humaner Molybdäncofaktor-Defizienz und anderer assoziierter Krankheiten

NULIBRY is a drug marketed by Sentynl Theraps Inc. There is one patent protecting this drug.

This drug has ten patent family members in ten countries.

The generic ingredient in NULIBRY is fosdenopterin hydrobromide. One supplier is listed for this generic product. Additional details are available on the fosdenopterin hydrobromide profile page.

Generic name: omega-3-carboxylic acids
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 13, 2024
Generic Entry Controlled by: Germany Patent 602,005,019,402

EPANOVA is a drug marketed by Astrazeneca. There are seven patents protecting this drug.

This drug has eighty-four patent family members in forty countries.

The generic ingredient in EPANOVA is omega-3-carboxylic acids. There is one drug master file entry for this API. Additional details are available on the omega-3-carboxylic acids profile page.

Generic name: ospemifene
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 23, 2024
Generic Entry Controlled by: Germany Patent 602,005,027,540

OSPHENA is a drug marketed by Duchesnay. There are eight patents protecting this drug.

This drug has ninety-four patent family members in thirty-one countries. There has been litigation on patents covering OSPHENA

See drug price trends for OSPHENA.

The generic ingredient in OSPHENA is ospemifene. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ospemifene profile page.

Generic name: fostemsavir tromethamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2024
Generic Entry Controlled by: Germany Patent 602,005,004,517

RUKOBIA is a drug marketed by Viiv Hlthcare. There are three patents protecting this drug.

This drug has thirty-nine patent family members in thirty countries.

See drug price trends for RUKOBIA.

The generic ingredient in RUKOBIA is fostemsavir tromethamine. One supplier is listed for this generic product. Additional details are available on the fostemsavir tromethamine profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Germany Patent 102,004,012,676
Patent Title: Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung (New glucopyranosyl-substituted benzene derivatives are sodium-dependent glucose cotransporter inhibitors, useful for treating e.g. metabolic disorders (type 1 and type 2 diabetes mellitus or metabolic acidosis))

SYNJARDY is a drug marketed by Boehringer Ingelheim. There are seven patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and ninety-two patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY

See drug price trends for SYNJARDY.

The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Germany Patent 102,004,040,168
Patent Title: Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung (New glucopyranosyl-substituted benzene derivatives are sodium-dependent glucose cotransporter inhibitors, useful for treating e.g. metabolic disorders (type 1 and type 2 diabetes mellitus or metabolic acidosis))

SYNJARDY is a drug marketed by Boehringer Ingelheim. There are seven patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and ninety-two patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY

See drug price trends for SYNJARDY.

The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Germany Patent 102,004,061,145
Patent Title: Glucopyranosyl-substituierte Benzol-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung (New glucopyranosyl-substituted benzene derivatives are sodium-dependent glucose cotransporter inhibitors, useful for treating e.g. metabolic disorders (type 1 and type 2 diabetes mellitus or metabolic acidosis))

SYNJARDY is a drug marketed by Boehringer Ingelheim. There are seven patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and ninety-two patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY

See drug price trends for SYNJARDY.

The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Germany Patent 602,005,009,745

SYNJARDY is a drug marketed by Boehringer Ingelheim. There are seven patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and ninety-two patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY

See drug price trends for SYNJARDY.

The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Germany Patent 102,004,012,676
Patent Title: Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung (New glucopyranosyl-substituted benzene derivatives are sodium-dependent glucose cotransporter inhibitors, useful for treating e.g. metabolic disorders (type 1 and type 2 diabetes mellitus or metabolic acidosis))

SYNJARDY XR is a drug marketed by Boehringer Ingelheim. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-six patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR

See drug price trends for SYNJARDY XR.

The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Germany Patent 102,004,040,168
Patent Title: Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung (New glucopyranosyl-substituted benzene derivatives are sodium-dependent glucose cotransporter inhibitors, useful for treating e.g. metabolic disorders (type 1 and type 2 diabetes mellitus or metabolic acidosis))

SYNJARDY XR is a drug marketed by Boehringer Ingelheim. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-six patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR

See drug price trends for SYNJARDY XR.

The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Germany Patent 102,004,061,145
Patent Title: Glucopyranosyl-substituierte Benzol-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung (New glucopyranosyl-substituted benzene derivatives are sodium-dependent glucose cotransporter inhibitors, useful for treating e.g. metabolic disorders (type 1 and type 2 diabetes mellitus or metabolic acidosis))

SYNJARDY XR is a drug marketed by Boehringer Ingelheim. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-six patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR

See drug price trends for SYNJARDY XR.

The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Germany Patent 602,005,009,745

SYNJARDY XR is a drug marketed by Boehringer Ingelheim. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-six patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR

See drug price trends for SYNJARDY XR.

The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Generic name: etonogestrel
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 19, 2024
Generic Entry Controlled by: Germany Patent 602,005,007,873

IMPLANON is a drug marketed by Organon. There is one patent protecting this drug.

This drug has thirty-two patent family members in twenty-six countries.

The generic ingredient in IMPLANON is etonogestrel. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the etonogestrel profile page.

Generic name: dienogest; estradiol valerate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 20, 2024
Generic Entry Controlled by: Germany Patent 102,004,019,743
Patent Title: Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens

NATAZIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has ninety patent family members in thirty-nine countries. There has been litigation on patents covering NATAZIA

See drug price trends for NATAZIA.

The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dienogest; estradiol valerate profile page.

Generic name: dienogest; estradiol valerate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 20, 2024
Generic Entry Controlled by: Germany Patent 502,005,009,904

NATAZIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has ninety patent family members in thirty-nine countries. There has been litigation on patents covering NATAZIA

See drug price trends for NATAZIA.

The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dienogest; estradiol valerate profile page.

Generic name: carfilzomib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: Germany Patent 602,005,026,556

KYPROLIS is a drug marketed by Onyx Therap. There are twelve patents protecting this drug and three Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and nineteen patent family members in forty-one countries. There has been litigation on patents covering KYPROLIS

See drug price trends for KYPROLIS.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.

Generic name: indacaterol maleate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Germany Patent 602,005,027,064

ARCAPTA NEOHALER is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has eighty-six patent family members in thirty-nine countries. There has been litigation on patents covering ARCAPTA NEOHALER

See drug price trends for ARCAPTA NEOHALER.

The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Additional details are available on the indacaterol maleate profile page.

Generic name: glycopyrrolate ; indacaterol maleate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Germany Patent 602,005,027,064

UTIBRON is a drug marketed by Novartis. There are three patents protecting this drug.

This drug has one hundred and forty-eight patent family members in forty countries. There has been litigation on patents covering UTIBRON

See drug price trends for UTIBRON.

The generic ingredient in UTIBRON is glycopyrrolate ; indacaterol maleate. There are seventeen drug master file entries for this API. Additional details are available on the glycopyrrolate ; indacaterol maleate profile page.

Generic name: vandetanib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 21, 2024
Generic Entry Controlled by: Germany Patent 602,005,016,105

CAPRELSA is a drug marketed by Genzyme Corp. There are three patents protecting this drug.

This drug has one hundred and forty-two patent family members in forty-three countries.

See drug price trends for CAPRELSA.

The generic ingredient in CAPRELSA is vandetanib. One supplier is listed for this generic product. Additional details are available on the vandetanib profile page.

Generic name: beclomethasone dipropionate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 21, 2024
Generic Entry Controlled by: Germany Patent 602,005,019,404

QNASL is a drug marketed by Teva Branded Pharm. There are two patents protecting this drug.

This drug has fifty-two patent family members in thirty-two countries.

See drug price trends for QNASL.

The generic ingredient in QNASL is beclomethasone dipropionate. There are twenty drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the beclomethasone dipropionate profile page.